Best practices from the sites perspective.
Insights into operational best practices
Non-alcoholic steatohepatitis (NASH) is a complicated disease that requires expertise across a broad spectrum of therapeutic areas, including hepatology, gastroenterology and endocrinology. As the prevalence of NASH continues to rise and the number of clinical trials is increasing, there is greater demand for patients and increased competition for site resources. In this challenging landscape, how can pharma and biotech companies ensure that their NASH trial sites are set up for success and best supported to drive the development of new therapies? We will provide perspectives on how to best partner with sites now and in the future to meet the growing demand for NASH patients while delivering high quality results.
Get insights and feedback from our extensive NASH study experience, and the findings from ICON’s recent survey of more than 2,000 sites across 30 countries. We will discuss the operational data compiled and shared through questionnaire responses on best practices for NASH study sites. Get insights on:
- How to best support global NASH sites to succeed in a competitive environment
- Optimising the operational strength of study sites to collectively support the NASH pipeline
- How understanding global and regional nuances can enhance NASH site patient recruitment and operational strategy
This webinar is intended for professionals from pharmaceutical, biotech, and medical device companies involved in:
- NASH Clinical Development
- Patient Recruitment
- Site Management
Program Manager, Clinical Project Management, Cardiovascular/Metabolic Therapeutics
Debbie has significant NASH experience, including seven NASH studies over the past five years, enrolling 888 patients in eight countries (US, CAN, UK, France, Germany, Italy, New Zealand, and Spain). Through her extensive NASH experience, Debbie maintains relationships with many US, UK, German, and Canadian NASH investigators. Additionally, she has collaborated with radiology and histopathology central readers, fostering key relationships throughout the NASH community.